1. 1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. (23rd October 2018) Authors: Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1584PExploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]. (1st October 2019) Authors: Pilotto, S; Vita, E; Sperduti, I; Noia, V P Di; Grizzi, G; D'Argento, E; Simbolo, M; Vicentini, C; Caliò, A; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Brunelli, M; Martini, M; Scarpa, A; Milella, M; Tortora, G; Bria, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 197PA propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC). (23rd October 2018) Authors: Carbognin, L; Sperduti, I; Arpino, G; Dieci, M V; Schettini, F; Griguolo, G; Brunelli, M; Guarneri, V; Nortilli, R; Fiorio, E; Pilotto, S; Orvieto, E; Manfrin, E; Conte, P; de Placido, S; Scambia, G; Tortora, G; Bria, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 202P_PRAdherence to dietary guidelines (DG) and body weight change (BWC) in early-stage breast cancer (EBC): A prospective trial in patients submitted to nutrition evidence-based educational intervention. (13th May 2019) Authors: Carbognin, L; Trestini, I; Sperduti, I; Fiorio, E; Tregnago, D; Pilotto, S; Scambia, G; Tortora, G; Milella, M; Bria, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?. Issue 6 (11th May 2005) Authors: Ferretti, G; Bria, E; Carlini, P; Felici, A; Giannarelli, D; Cuppone, F; Papaldo, P; Nisticò, C; Fabi, A; Gelibter, A; Terzoli, E; Cognetti, F Journal: Gut Issue: Volume 54:Issue 6(2005) Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-139Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study). (2nd July 2019) Authors: Calegari, M; Zurlo, I; Basso, M; Orlandi, A; Bensi, M; Camarda, F; Stefano, B Di; Vivolo, R; Pozzo, C; Sperduti, I; Bria, E; Salvatore, L; Tortora, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P-317Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study). (2nd July 2019) Authors: Bensi, M; Calegari, M; Basso, M; Orlandi, A; Boccaccino, A; Lombardo, F; Zurlo, I; Stefano, B Di; Camarda, F; Vivolo, R; Cocomazzi, A; Martini, M; Auriemma, A; Pozzo, C; Bria, E; Salvatore, L; Tortora, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PD-021Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies. (2nd July 2019) Authors: Salvatore, L; Bria, E; Sperduti, I; Hinke, A; Hegewisch-Becker, S; Aparicio, T; Le Malicot, K; Boige, V; Koeberle, D; Baertschi, D; Dietrich, D; Tortora, G; Arnold, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. (26th April 2018) Authors: Loibl, S; Majewski, I; Guarneri, V; Nekljudova, V; Holmes, E; Bria, E; Denkert, C; Schem, C; Sotiriou, C; Loi, S; Untch, M; Conte, P; Bernards, R; Piccart, M; von Minckwitz, G; Baselga, J Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗